How large is the checkpoint inhibitors market, and what is its growth trajectory?
The checkpoint inhibitors market size has grown rapidly in recent years. It will grow from $32.41 billion in 2024 to $37.88 billion in 2025 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to rising incidence of cancer, increasing awareness of checkpoint inhibitors, expanding range of approved checkpoint inhibitors, research and development on checkpoints novel inhibitors, clinical trials and research.
The checkpoint inhibitors market size is expected to see rapid growth in the next few years. It will grow to $55.64 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to expanding indications, biomarker discovery, combination therapies, personalized medicine, and expanded indications. Major trends in the forecast period include precision immunotherapy, immune checkpoint combinations, cell therapy integration, biosimilars, and immunotherapy combinations.
Get Your Free Sample of The Global Checkpoint Inhibitors Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3413&type=smp
What are the key forces behind the checkpoint inhibitors market’s growth in recent years?
The rise in the number of cancer cases across the globe is expected to propel the growth of the checkpoint inhibitors market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body, which can invade surrounding tissues and potentially spread to other parts of the body. The rise in cancer is driven by factors such as aging populations, unhealthy lifestyles (smoking, poor diet), environmental exposures (pollution, radiation), genetic predispositions, and infections like HPV and hepatitis. Checkpoint inhibitors block proteins that restrict immune cells, enabling the immune system to recognize and attack cancer cells more effectively. For instance, in September 2024, according to American Cancer Society, a US-based Professional organizations company, by 2050, global cancer cases in men will rise by 84%, increasing from 10.3 million in 2022 to 19 million, while cancer deaths are projected to increase by 93%, from 5.4 million in 2022 to 10.5 million. Therefore, the rise in cancer incidence rates globally is anticipated to boost for checkpoint inhibitors market demand.
What are the major segments of the checkpoint inhibitors market?
The checkpoint inhibitors market covered in this report is segmented –
1) By Drug: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Other Drugs
2) By Application: Lung Cancer, Renal Cancer, Blood Cancer, Bladder Cancer, Melanoma, Other Applications
3) By End-Users: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By PD-1 Inhibitors: Pembrolizumab (Keytruda), Nivolumab (Opdivo)
2) By PD-L1 Inhibitors: Atezolizumab (Tecentriq), Durvalumab (Imfinzi), Avelumab (Bavencio)
3) By CTLA-4: Ipilimumab (Yervoy)
4) By Chimeric Antigen Receptor T-cell: CAR T-cell Therapy Products
5) By Other Drugs: Combination Therapies, Emerging Checkpoint Inhibitors
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report
Which companies dominate the checkpoint inhibitors market?
Major companies operating in the checkpoint inhibitors market include AstraZeneca plc, Bristol-Myers Squibb Company, Merck & Co. Inc., Roche Holding AG, Pfizer Inc., Incyte Corporation, Novartis AG, GlaxoSmithKline plc, Innate Pharma S.A., Ono Pharmaceutical Co. Ltd., Eli Lilly and Company, Sanofi S.A, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bayer AG, Boehringer Ingelheim International GmbH, Celgene Corporation, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Kyowa Kirin Co. Ltd., Johnson & Johnson, Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Zai Lab Limited
How will evolving trends contribute to the growth of the checkpoint inhibitors market?
Major companies in the checkpoint inhibitor market are forming development of advanced technologies such as oral checkpoint inhibitor. Most patients with cancer do not respond to immune checkpoint inhibitors. An oral checkpoint inhibitor is a type of cancer immunotherapy drug designed to be taken by mouth, which blocks immune checkpoints such as PD-1/PD-L1, helping the immune system recognize and attack cancer cells. For instance, in September 2024, OmRx Oncology, a US-based biopharmaceutical company, launched OX-4224, an oral checkpoint inhibitor targeting the PD-1/PD-L1 pathway for non-small cell lung cancer (NSCLC). This investigational drug aims to provide a more affordable alternative to biologic checkpoint inhibitors, increasing global access to cancer immunotherapy. A Phase 2 study in India will assess its safety and efficacy in patients with advanced NSCLC. OmRx plans to expand its use to low and middle-income countries, focusing on improving global cancer care.
Which geographic trends are shaping the checkpoint inhibitors market, and which region has the highest market share?
North America was the largest region in the checkpoint inhibitors market in 2024. The Middle East is expected to be the fastest growing region in the global checkpoint inhibitors market share during the forecast period. The regions covered in the checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
What Does The Checkpoint Inhibitors Market Report 2025 Offer?
The checkpoint inhibitors market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Checkpoint inhibitors refer to an immunotherapy strategy that prevents immune checkpoint proteins from forming interactions with other proteins. Because of this, the T cells can destroy cancer cells because the ‘off’ signal is not sent. One such medication works against the checkpoint protein CTLA-4.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3413
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
